ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Tumor Immune Cell Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-28T17280
Home | Market Reports | Health| Health Conditions| Cancer
Global Tumor Immune Cell Therapy Market Research Report 2024
BUY CHAPTERS

Global Tumor Immune Cell Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-28T17280
Report
October 2025
Pages:152
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Medinet
Erytech
Seta Clinic Group
Takeda
SBI Holdings
Oxford BioTherapeutics
Fate Therapeutics
Gilead Sciences
Novartis
Osiris
Vericel Corporation
Fujifilm Cellular Dynamics
JCR Pharmaceuticals
Beike Biotechnology
Golden Meditech
Guanhao Biotech
Beroni Group
Legend Biotech

Tumor Immune Cell Therapy Market

The global Tumor Immune Cell Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Cancer immune cell therapy is a treatment method that activates the function of the patient's own immune cells, thereby enhancing the immune cells' ability to attack cancer and inhibit cancer cells. In actual treatment, we extract immune cells involved in attacking cancer from the patient's blood, cancer tissue, ascites, and pleural effusion, proliferate, activate, and enhance their functions in vitro before returning them to the patient.
From a downstream perspective, Hematological Tumors accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Tumor Immune Cell Therapy leading manufacturers including MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, Oxford BioTherapeutics, Fate Therapeutics, Gilead Sciences, Novartis, Osiris, etc., dominate supply; the top five capture approximately % of global revenue, with MEDINET Co leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Tumor Immune Cell Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Tumor Immune Cell Therapy Market Report

Report Metric Details
Report Name Tumor Immune Cell Therapy Market
Segment by Type
  • Immune Checkpoint Inhibitors
  • Chimeric Antigen Receptor T-cell Therapy
  • Tumor-Infiltrating Lymphocytes Therapy
  • Cancer Vaccines
  • Bispecific Antibodies
  • Cytokine Therapy
Segment by Application
  • Hematological Tumors
  • Solid Tumors
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, Oxford BioTherapeutics, Fate Therapeutics, Gilead Sciences, Novartis, Osiris, Vericel Corporation, Fujifilm Cellular Dynamics, JCR Pharmaceuticals, Beike Biotechnology, Golden Meditech, Guanhao Biotech, Beroni Group, Legend Biotech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Tumor Immune Cell Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Tumor Immune Cell Therapy Market report?

Ans: The main players in the Tumor Immune Cell Therapy Market are MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, Oxford BioTherapeutics, Fate Therapeutics, Gilead Sciences, Novartis, Osiris, Vericel Corporation, Fujifilm Cellular Dynamics, JCR Pharmaceuticals, Beike Biotechnology, Golden Meditech, Guanhao Biotech, Beroni Group, Legend Biotech

What are the Application segmentation covered in the Tumor Immune Cell Therapy Market report?

Ans: The Applications covered in the Tumor Immune Cell Therapy Market report are Hematological Tumors, Solid Tumors

What are the Type segmentation covered in the Tumor Immune Cell Therapy Market report?

Ans: The Types covered in the Tumor Immune Cell Therapy Market report are Immune Checkpoint Inhibitors, Chimeric Antigen Receptor T-cell Therapy, Tumor-Infiltrating Lymphocytes Therapy, Cancer Vaccines, Bispecific Antibodies, Cytokine Therapy

1 Study Coverage
1.1 Introduction to Tumor Immune Cell Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Tumor Immune Cell Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Chimeric Antigen Receptor T-cell Therapy
1.2.4 Tumor-Infiltrating Lymphocytes Therapy
1.2.5 Cancer Vaccines
1.2.6 Bispecific Antibodies
1.2.7 Cytokine Therapy
1.3 Market Segmentation by Application
1.3.1 Global Tumor Immune Cell Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hematological Tumors
1.3.3 Solid Tumors
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Tumor Immune Cell Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Tumor Immune Cell Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Tumor Immune Cell Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Tumor Immune Cell Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Immune Checkpoint Inhibitors Market Size by Players
3.3.2 Chimeric Antigen Receptor T-cell Therapy Market Size by Players
3.3.3 Tumor-Infiltrating Lymphocytes Therapy Market Size by Players
3.3.4 Cancer Vaccines Market Size by Players
3.3.5 Bispecific Antibodies Market Size by Players
3.3.6 Cytokine Therapy Market Size by Players
3.4 Global Tumor Immune Cell Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Tumor Immune Cell Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Tumor Immune Cell Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Tumor Immune Cell Therapy Market Size by Type (2020-2031)
6.4 North America Tumor Immune Cell Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Tumor Immune Cell Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Tumor Immune Cell Therapy Market Size by Type (2020-2031)
7.4 Europe Tumor Immune Cell Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Tumor Immune Cell Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Tumor Immune Cell Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Tumor Immune Cell Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Tumor Immune Cell Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Tumor Immune Cell Therapy Market Size by Type (2020-2031)
9.4 Central and South America Tumor Immune Cell Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Tumor Immune Cell Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Tumor Immune Cell Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Tumor Immune Cell Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Tumor Immune Cell Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 MEDINET Co
11.1.1 MEDINET Co Corporation Information
11.1.2 MEDINET Co Business Overview
11.1.3 MEDINET Co Tumor Immune Cell Therapy Product Features and Attributes
11.1.4 MEDINET Co Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.1.5 MEDINET Co Tumor Immune Cell Therapy Revenue by Product in 2024
11.1.6 MEDINET Co Tumor Immune Cell Therapy Revenue by Application in 2024
11.1.7 MEDINET Co Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.1.8 MEDINET Co Tumor Immune Cell Therapy SWOT Analysis
11.1.9 MEDINET Co Recent Developments
11.2 Erytech
11.2.1 Erytech Corporation Information
11.2.2 Erytech Business Overview
11.2.3 Erytech Tumor Immune Cell Therapy Product Features and Attributes
11.2.4 Erytech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Erytech Tumor Immune Cell Therapy Revenue by Product in 2024
11.2.6 Erytech Tumor Immune Cell Therapy Revenue by Application in 2024
11.2.7 Erytech Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.2.8 Erytech Tumor Immune Cell Therapy SWOT Analysis
11.2.9 Erytech Recent Developments
11.3 Seta Clinic Group
11.3.1 Seta Clinic Group Corporation Information
11.3.2 Seta Clinic Group Business Overview
11.3.3 Seta Clinic Group Tumor Immune Cell Therapy Product Features and Attributes
11.3.4 Seta Clinic Group Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Seta Clinic Group Tumor Immune Cell Therapy Revenue by Product in 2024
11.3.6 Seta Clinic Group Tumor Immune Cell Therapy Revenue by Application in 2024
11.3.7 Seta Clinic Group Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.3.8 Seta Clinic Group Tumor Immune Cell Therapy SWOT Analysis
11.3.9 Seta Clinic Group Recent Developments
11.4 Takeda
11.4.1 Takeda Corporation Information
11.4.2 Takeda Business Overview
11.4.3 Takeda Tumor Immune Cell Therapy Product Features and Attributes
11.4.4 Takeda Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Takeda Tumor Immune Cell Therapy Revenue by Product in 2024
11.4.6 Takeda Tumor Immune Cell Therapy Revenue by Application in 2024
11.4.7 Takeda Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.4.8 Takeda Tumor Immune Cell Therapy SWOT Analysis
11.4.9 Takeda Recent Developments
11.5 SBI Holdings
11.5.1 SBI Holdings Corporation Information
11.5.2 SBI Holdings Business Overview
11.5.3 SBI Holdings Tumor Immune Cell Therapy Product Features and Attributes
11.5.4 SBI Holdings Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.5.5 SBI Holdings Tumor Immune Cell Therapy Revenue by Product in 2024
11.5.6 SBI Holdings Tumor Immune Cell Therapy Revenue by Application in 2024
11.5.7 SBI Holdings Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.5.8 SBI Holdings Tumor Immune Cell Therapy SWOT Analysis
11.5.9 SBI Holdings Recent Developments
11.6 Oxford BioTherapeutics
11.6.1 Oxford BioTherapeutics Corporation Information
11.6.2 Oxford BioTherapeutics Business Overview
11.6.3 Oxford BioTherapeutics Tumor Immune Cell Therapy Product Features and Attributes
11.6.4 Oxford BioTherapeutics Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Oxford BioTherapeutics Recent Developments
11.7 Fate Therapeutics
11.7.1 Fate Therapeutics Corporation Information
11.7.2 Fate Therapeutics Business Overview
11.7.3 Fate Therapeutics Tumor Immune Cell Therapy Product Features and Attributes
11.7.4 Fate Therapeutics Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Fate Therapeutics Recent Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Corporation Information
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Tumor Immune Cell Therapy Product Features and Attributes
11.8.4 Gilead Sciences Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Gilead Sciences Recent Developments
11.9 Novartis
11.9.1 Novartis Corporation Information
11.9.2 Novartis Business Overview
11.9.3 Novartis Tumor Immune Cell Therapy Product Features and Attributes
11.9.4 Novartis Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Novartis Recent Developments
11.10 Osiris
11.10.1 Osiris Corporation Information
11.10.2 Osiris Business Overview
11.10.3 Osiris Tumor Immune Cell Therapy Product Features and Attributes
11.10.4 Osiris Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Vericel Corporation
11.11.1 Vericel Corporation Corporation Information
11.11.2 Vericel Corporation Business Overview
11.11.3 Vericel Corporation Tumor Immune Cell Therapy Product Features and Attributes
11.11.4 Vericel Corporation Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.11.5 Vericel Corporation Recent Developments
11.12 Fujifilm Cellular Dynamics
11.12.1 Fujifilm Cellular Dynamics Corporation Information
11.12.2 Fujifilm Cellular Dynamics Business Overview
11.12.3 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Product Features and Attributes
11.12.4 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.12.5 Fujifilm Cellular Dynamics Recent Developments
11.13 JCR Pharmaceuticals
11.13.1 JCR Pharmaceuticals Corporation Information
11.13.2 JCR Pharmaceuticals Business Overview
11.13.3 JCR Pharmaceuticals Tumor Immune Cell Therapy Product Features and Attributes
11.13.4 JCR Pharmaceuticals Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.13.5 JCR Pharmaceuticals Recent Developments
11.14 Beike Biotechnology
11.14.1 Beike Biotechnology Corporation Information
11.14.2 Beike Biotechnology Business Overview
11.14.3 Beike Biotechnology Tumor Immune Cell Therapy Product Features and Attributes
11.14.4 Beike Biotechnology Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.14.5 Beike Biotechnology Recent Developments
11.15 Golden Meditech
11.15.1 Golden Meditech Corporation Information
11.15.2 Golden Meditech Business Overview
11.15.3 Golden Meditech Tumor Immune Cell Therapy Product Features and Attributes
11.15.4 Golden Meditech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.15.5 Golden Meditech Recent Developments
11.16 Guanhao Biotech
11.16.1 Guanhao Biotech Corporation Information
11.16.2 Guanhao Biotech Business Overview
11.16.3 Guanhao Biotech Tumor Immune Cell Therapy Product Features and Attributes
11.16.4 Guanhao Biotech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.16.5 Guanhao Biotech Recent Developments
11.17 Beroni Group
11.17.1 Beroni Group Corporation Information
11.17.2 Beroni Group Business Overview
11.17.3 Beroni Group Tumor Immune Cell Therapy Product Features and Attributes
11.17.4 Beroni Group Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.17.5 Beroni Group Recent Developments
11.18 Legend Biotech
11.18.1 Legend Biotech Corporation Information
11.18.2 Legend Biotech Business Overview
11.18.3 Legend Biotech Tumor Immune Cell Therapy Product Features and Attributes
11.18.4 Legend Biotech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.18.5 Legend Biotech Recent Developments
12 Tumor Immune Cell TherapyIndustry Chain Analysis
12.1 Tumor Immune Cell Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Tumor Immune Cell Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Tumor Immune Cell Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Medinet
Erytech
Seta Clinic Group
Takeda
SBI Holdings
Oxford BioTherapeutics
Fate Therapeutics
Gilead Sciences
Novartis
Osiris
Vericel Corporation
Fujifilm Cellular Dynamics
JCR Pharmaceuticals
Beike Biotechnology
Golden Meditech
Guanhao Biotech
Beroni Group
Legend Biotech
List of Tables
 Table 1. Global Tumor Immune Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Tumor Immune Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Tumor Immune Cell Therapy Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Tumor Immune Cell Therapy Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Tumor Immune Cell Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Tumor Immune Cell Therapy Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Tumor Immune Cell Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immune Cell Therapy as of 2024)
 Table 11. Global Tumor Immune Cell Therapy Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Tumor Immune Cell Therapy Companies Headquarters
 Table 13. Global Tumor Immune Cell Therapy Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Tumor Immune Cell Therapy Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Tumor Immune Cell Therapy Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Tumor Immune Cell Therapy Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Tumor Immune Cell Therapy Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Tumor Immune Cell Therapy High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Tumor Immune Cell Therapy Growth Accelerators and Market Barriers
 Table 25. North America Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Tumor Immune Cell Therapy Growth Accelerators and Market Barriers
 Table 27. Europe Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Tumor Immune Cell Therapy Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Tumor Immune Cell Therapy Investment Opportunities and Key Challenges
 Table 31. Central and South America Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Tumor Immune Cell Therapy Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. MEDINET Co Corporation Information
 Table 35. MEDINET Co Description and Major Businesses
 Table 36. MEDINET Co Product Features and Attributes
 Table 37. MEDINET Co Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. MEDINET Co Revenue Proportion by Product in 2024
 Table 39. MEDINET Co Revenue Proportion by Application in 2024
 Table 40. MEDINET Co Revenue Proportion by Geographic Area in 2024
 Table 41. MEDINET Co Tumor Immune Cell Therapy SWOT Analysis
 Table 42. MEDINET Co Recent Developments
 Table 43. Erytech Corporation Information
 Table 44. Erytech Description and Major Businesses
 Table 45. Erytech Product Features and Attributes
 Table 46. Erytech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Erytech Revenue Proportion by Product in 2024
 Table 48. Erytech Revenue Proportion by Application in 2024
 Table 49. Erytech Revenue Proportion by Geographic Area in 2024
 Table 50. Erytech Tumor Immune Cell Therapy SWOT Analysis
 Table 51. Erytech Recent Developments
 Table 52. Seta Clinic Group Corporation Information
 Table 53. Seta Clinic Group Description and Major Businesses
 Table 54. Seta Clinic Group Product Features and Attributes
 Table 55. Seta Clinic Group Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Seta Clinic Group Revenue Proportion by Product in 2024
 Table 57. Seta Clinic Group Revenue Proportion by Application in 2024
 Table 58. Seta Clinic Group Revenue Proportion by Geographic Area in 2024
 Table 59. Seta Clinic Group Tumor Immune Cell Therapy SWOT Analysis
 Table 60. Seta Clinic Group Recent Developments
 Table 61. Takeda Corporation Information
 Table 62. Takeda Description and Major Businesses
 Table 63. Takeda Product Features and Attributes
 Table 64. Takeda Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Takeda Revenue Proportion by Product in 2024
 Table 66. Takeda Revenue Proportion by Application in 2024
 Table 67. Takeda Revenue Proportion by Geographic Area in 2024
 Table 68. Takeda Tumor Immune Cell Therapy SWOT Analysis
 Table 69. Takeda Recent Developments
 Table 70. SBI Holdings Corporation Information
 Table 71. SBI Holdings Description and Major Businesses
 Table 72. SBI Holdings Product Features and Attributes
 Table 73. SBI Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. SBI Holdings Revenue Proportion by Product in 2024
 Table 75. SBI Holdings Revenue Proportion by Application in 2024
 Table 76. SBI Holdings Revenue Proportion by Geographic Area in 2024
 Table 77. SBI Holdings Tumor Immune Cell Therapy SWOT Analysis
 Table 78. SBI Holdings Recent Developments
 Table 79. Oxford BioTherapeutics Corporation Information
 Table 80. Oxford BioTherapeutics Description and Major Businesses
 Table 81. Oxford BioTherapeutics Product Features and Attributes
 Table 82. Oxford BioTherapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Oxford BioTherapeutics Recent Developments
 Table 84. Fate Therapeutics Corporation Information
 Table 85. Fate Therapeutics Description and Major Businesses
 Table 86. Fate Therapeutics Product Features and Attributes
 Table 87. Fate Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Fate Therapeutics Recent Developments
 Table 89. Gilead Sciences Corporation Information
 Table 90. Gilead Sciences Description and Major Businesses
 Table 91. Gilead Sciences Product Features and Attributes
 Table 92. Gilead Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Gilead Sciences Recent Developments
 Table 94. Novartis Corporation Information
 Table 95. Novartis Description and Major Businesses
 Table 96. Novartis Product Features and Attributes
 Table 97. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Novartis Recent Developments
 Table 99. Osiris Corporation Information
 Table 100. Osiris Description and Major Businesses
 Table 101. Osiris Product Features and Attributes
 Table 102. Osiris Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Osiris Recent Developments
 Table 104. Vericel Corporation Corporation Information
 Table 105. Vericel Corporation Description and Major Businesses
 Table 106. Vericel Corporation Product Features and Attributes
 Table 107. Vericel Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Vericel Corporation Recent Developments
 Table 109. Fujifilm Cellular Dynamics Corporation Information
 Table 110. Fujifilm Cellular Dynamics Description and Major Businesses
 Table 111. Fujifilm Cellular Dynamics Product Features and Attributes
 Table 112. Fujifilm Cellular Dynamics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Fujifilm Cellular Dynamics Recent Developments
 Table 114. JCR Pharmaceuticals Corporation Information
 Table 115. JCR Pharmaceuticals Description and Major Businesses
 Table 116. JCR Pharmaceuticals Product Features and Attributes
 Table 117. JCR Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. JCR Pharmaceuticals Recent Developments
 Table 119. Beike Biotechnology Corporation Information
 Table 120. Beike Biotechnology Description and Major Businesses
 Table 121. Beike Biotechnology Product Features and Attributes
 Table 122. Beike Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. Beike Biotechnology Recent Developments
 Table 124. Golden Meditech Corporation Information
 Table 125. Golden Meditech Description and Major Businesses
 Table 126. Golden Meditech Product Features and Attributes
 Table 127. Golden Meditech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 128. Golden Meditech Recent Developments
 Table 129. Guanhao Biotech Corporation Information
 Table 130. Guanhao Biotech Description and Major Businesses
 Table 131. Guanhao Biotech Product Features and Attributes
 Table 132. Guanhao Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 133. Guanhao Biotech Recent Developments
 Table 134. Beroni Group Corporation Information
 Table 135. Beroni Group Description and Major Businesses
 Table 136. Beroni Group Product Features and Attributes
 Table 137. Beroni Group Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 138. Beroni Group Recent Developments
 Table 139. Legend Biotech Corporation Information
 Table 140. Legend Biotech Description and Major Businesses
 Table 141. Legend Biotech Product Features and Attributes
 Table 142. Legend Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 143. Legend Biotech Recent Developments
 Table 144. Raw Materials Key Suppliers
 Table 145. Distributors List
 Table 146. Market Trends and Market Evolution
 Table 147. Market Drivers and Opportunities
 Table 148. Market Challenges, Risks, and Restraints
 Table 149. Research Programs/Design for This Report
 Table 150. Key Data Information from Secondary Sources
 Table 151. Key Data Information from Primary Sources


List of Figures
 Figure 1. Tumor Immune Cell Therapy Product Picture
 Figure 2. Global Tumor Immune Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Immune Checkpoint Inhibitors Product Picture
 Figure 4. Chimeric Antigen Receptor T-cell Therapy Product Picture
 Figure 5. Tumor-Infiltrating Lymphocytes Therapy Product Picture
 Figure 6. Cancer Vaccines Product Picture
 Figure 7. Bispecific Antibodies Product Picture
 Figure 8. Cytokine Therapy Product Picture
 Figure 9. Global Tumor Immune Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 10. Hematological Tumors
 Figure 11. Solid Tumors
 Figure 12. Tumor Immune Cell Therapy Report Years Considered
 Figure 13. Global Tumor Immune Cell Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 15. Global Tumor Immune Cell Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 16. Global Tumor Immune Cell Therapy Revenue Market Share by Region (2020-2031)
 Figure 17. Global Tumor Immune Cell Therapy Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Immune Checkpoint Inhibitors Revenue Market Share by Player in 2024
 Figure 20. Chimeric Antigen Receptor T-cell Therapy Revenue Market Share by Player in 2024
 Figure 21. Tumor-Infiltrating Lymphocytes Therapy Revenue Market Share by Player in 2024
 Figure 22. Cancer Vaccines Revenue Market Share by Player in 2024
 Figure 23. Bispecific Antibodies Revenue Market Share by Player in 2024
 Figure 24. Cytokine Therapy Revenue Market Share by Player in 2024
 Figure 25. Global Tumor Immune Cell Therapy Revenue Market Share by Type (2020-2031)
 Figure 26. Global Tumor Immune Cell Therapy Revenue Market Share by Application (2020-2031)
 Figure 27. North America Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. North America Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
 Figure 29. North America Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 31. US Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 32. Canada Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 33. Mexico Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 34. Europe Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 35. Europe Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
 Figure 36. Europe Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 37. Europe Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 38. Germany Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 39. France Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 40. U.K. Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 41. Italy Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 42. Russia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 43. Asia-Pacific Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 44. Asia-Pacific Top 8 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
 Figure 45. Asia-Pacific Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 46. Asia-Pacific Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 47. Indonesia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 48. Japan Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 49. South Korea Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 50. Australia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 51. India Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 52. Indonesia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 53. Vietnam Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 54. Malaysia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 55. Philippines Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 56. Singapore Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
 Figure 57. Central and South America Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Central and South America Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
 Figure 59. Central and South America Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 60. Central and South America Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 61. Brazil Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 62. Argentina Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 63. Middle East and Africa Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 64. Middle East and Africa Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
 Figure 65. South America Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 66. Middle East and Africa Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 67. GCC Countries Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 68. Israel Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 69. Egypt Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 70. South Africa Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
 Figure 71. Tumor Immune Cell Therapy Industry Chain Mapping
 Figure 72. Channels of Distribution (Direct Vs Distribution)
 Figure 73. Bottom-up and Top-down Approaches for This Report
 Figure 74. Data Triangulation
 Figure 75. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Immune Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immuno Cell Therapy Market Research Report 2024
Global Immune Cell Therapy Drugs Market Research Report 2025
Global Cell Immunotherapy Platform Market Research Report 2024
Natural Killer NK Cell Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global NK Cell Therapy Market Insights Forecast to 2030
Global Cancer Immunosuppressant Treatment Market Research Report 2024
Global Cancer Immuno Personalized Medicine Market Research Report 2024
Global Cancer Immunotherapy Drugs Market Research Report 2024
Global Immunosuppressants in Cancer Therapy Market Research Report 2024
Global Immunotherapy Drugs Market Research Report 2024
Global Immuno oncology Therapy Market Insights Forecast to 2030
Global Immunocell Therapy Market Insights Forecast to 2030
Global Natural Killer Cell Therapy Market Insights Forecast to 2030
Global Adoptive Cell Therapy Market Insights Forecast to 2030
Global Natural Killer Cells Therapeutics Market Insights Forecast to 2030
Global Natural Killer Cell Therapeutics Market Research Report 2024
Global T Cell Immunotherapy Market Research Report 2025
Engineered Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cell Therapy Market Insights Forecast to 2030

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions